Metrics to compare | POLB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPOLBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.6x | −1.1x | −0.5x | |
PEG Ratio | −0.28 | 0.01 | 0.00 | |
Price / Book | 3.7x | 1.3x | 2.6x | |
Price / LTM Sales | - | 1.5x | 3.3x | |
Upside (Analyst Target) | 347.1% | 147.6% | 47.1% | |
Fair Value Upside | Unlock | 16.1% | 6.2% | Unlock |
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.